YOLFTbeta
Atrium Therapeutics, Inc. Common Stock

Atrium Therapeutics, Inc. Common Stock

RNA · NASDAQ · Healthcare / Biotechnology

7.51USD+0.01 (+0.13%)

Price History

Full chart

Market Stats

Previous Close7.50
Open7.71
Day Range7.47 – 7.83
52-Week Range8.05 – 16.77
Volume195.17K
Market Cap141.81M
P/E (TTM)0.00
Forward P/E0.00
EPS-5.44
Dividend Yield0.00%
Beta0.93
50-Day Avg11.86
200-Day Avg12.79

About

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Kathleen P. Gallagher
  • Employees511
  • Headquarters10578 Science Center Drive, San Diego, CA, United States, 92121, USA
  • Websitehttps://atriumtherapeutics.com

Leadership

  • Ms. Kathleen P. GallagherPresident, CEO & Director · b. 1981
  • Mr. Brendan WinslowChief Financial Officer · b. 1988
  • Dr. Husam Younis Ph.D., Pharm.D.Chief Scientific Officer · b. 1974
  • Ms. Stephanie KenneyChief Corporate Affairs Officer · b. 1978
  • Dr. Steven George Hughes M.B.A., M.D.Chief Medical Officer · b. 1967
  • Ms. Rocio Martin HoyosChief Strategy Officer · b. 1983

Financials

Income Statement

Currency: USD2011-12-312012-12-312013-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue11.27M10.36M13.09M379.00K2.32M6.79M9.33M9.22M9.56M10.90M18.62M
Growth (%)--8.14%+26.39%-97.10%+511.87%+192.67%+37.41%-1.09%+3.64%+13.99%+70.85%
Cost of Revenue25.28M22.75M32.51M8.44M14.54M37.60M639.00K1.39M2.10M2.78M4.15M
Gross Profit----8.06M2.32M6.79M9.33M9.22M7.46M10.90M18.62M
Gross Margin----2125.86%100.00%100.00%100.00%100.00%78.02%100.00%100.00%
Operating Expense---2.44M19.65M51.06M127.38M188.14M243.06M389.83M95.43M
Operating Income----10.50M-17.33M-44.28M-118.05M-178.91M-235.60M-378.94M-76.81M
Operating Margin----2769.92%-747.39%-652.38%-1265.83%-1939.65%-2464.41%-3477.43%-412.58%
EBITDA----10.12M-17.00M-43.90M-117.41M-177.53M-233.50M-376.16M-76.50M
EBITDA Margin----2668.87%-733.03%-646.88%-1258.97%-1924.61%-2442.44%-3451.96%-410.91%
Net Income----11.93M-24.73M-43.98M-117.37M-169.08M-212.22M-322.30M-76.68M
Net Income Margin----3148.81%-1066.58%-648.03%-1258.52%-1833.01%-2219.87%-2957.71%-411.88%
R&D19.91M18.98M25.44M8.44M14.54M37.60M101.18M150.40M190.97M303.59M53.76M
R&D as % of Total Revenue176.64%183.28%194.35%2225.86%626.95%554.03%1084.95%1630.57%1997.57%2786.02%288.73%
Interest Expense000718.00K7.39M209.00K639.00K5.69M---
Interest Expense % of Total Revenue0.00%0.00%0.00%189.45%318.54%3.08%6.85%61.69%---

Balance Sheet

Currency: USD2011-12-312012-12-312013-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets32.68M62.41M125.10M3.98M96.91M333.90M427.58M638.80M628.55M1.56B278.35M
Total Liabilities29.27M41.87M38.00M45.11M162.26M27.68M46.15M60.73M127.79M138.94M71.07M
Total Equity3.41M20.54M87.10M-41.13M-65.36M306.22M381.43M578.08M500.76M1.42B207.29M
Cash24.32M53.72M113.31M3.09M94.58M328.14M320.45M340.40M185.08M219.87M270.00M
Total Debt---10.32M4.94M938.00K11.73M10.69M9.85M6.80M3.67M
Net Debt---7.23M-89.64M-327.20M-308.72M-329.71M-175.23M-213.07M-266.33M

Cash Flow

Currency: USD2011-12-312012-12-312013-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow----9.65M2.49M-37.12M-94.81M-136.27M-119.06M-300.87M-41.13M
Investing Cash Flow----49.00K-235.00K-7.79M-82.52M-189.96M-130.07M-854.20M-1.45M
Financing Cash Flow594.00K34.32M88.02M5.14M89.23M272.04M176.32M346.17M93.86M1.19B42.57M
Capital Expenditure2.60M309.00K834.00K49.00K235.00K1.09M3.74M2.82M4.23M7.07M1.45M
Free Cash Flow----9.70M2.25M-38.21M-98.55M-139.09M-123.29M-307.94M-42.57M
Dividends Paid---106.00K106.00K444.00K0----
FCF to OCF---100.51%90.56%102.94%103.94%102.07%103.55%102.35%103.51%
Dividend Paid to FCF----1.09%4.70%-1.16%0.00%----

Earnings

Report DateDec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Jun 8, 2020Aug 10, 2020Nov 10, 2020Mar 15, 2021May 12, 2021Aug 9, 2021Nov 9, 2021Mar 1, 2022May 10, 2022Aug 9, 2022Nov 8, 2022Feb 28, 2023May 9, 2023Aug 8, 2023Nov 8, 2023Feb 28, 2024May 9, 2024Aug 9, 2024Nov 7, 2024Feb 26, 2025May 8, 2025Aug 7, 2025Nov 10, 2025Feb 23, 2026May 14, 2026Aug 13, 2026Nov 12, 2026
EPS Estimate-0.12-0.03-0.25-0.23-1.58-0.36-0.43-0.34-0.56-0.71-0.68-0.70-0.83-0.77-0.93-0.89-0.86-0.79-0.75-0.66-0.88-0.78-0.72-0.78-0.88-0.96-1.10-1.26-1.05-0.64-1.70
EPS Actual-0.110.19-0.22-0.29-0.56-1.23-0.31-0.43-0.64-0.70-0.68-0.82-0.71-0.92-0.82-0.88-0.74-0.66-0.71-0.79-0.79-0.65-0.65-0.80-0.90-1.21-1.27-1.59-0.97-1.18-
Surprise8.33%733.33%12.00%-26.09%64.56%-241.67%27.91%-26.47%-14.29%1.41%0.00%-17.14%14.46%-19.48%11.83%1.12%13.95%16.46%5.33%-19.70%10.23%16.67%9.72%-2.45%-2.27%-26.04%-15.45%-26.19%7.62%-84.38%-
Timing----After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-

Key Statistics & Ratios

Market Cap141.81M
Enterprise Value-119.90M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales3.96
Price / Book0.66
EPS-5.44
Book Value12.54
Revenue (TTM)35.84M
Gross Profit (TTM)-20.20M
EBITDA-68.53M
Profit Margin-184.15%
Operating Margin-752.93%
Return on Equity-43.98%
Return on Assets-399.25%
Shares Outstanding17.11M
Shares Float15.04M
Beta0.93
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 15 analystsTarget 25.00
  • Strong Buy
    9
  • Buy
    6

Ownership Breakdown

Institutions
84.46%
Insiders
4.16%
Retail / Other
11.38%

Top Institutional Holders

  • CIBC Bancorp USA Inc.
    00.00%
  • Arizona State Retirement System
    00.00%
  • Capital Analysts Inc.
    00.00%
  • Acadian Asset Management LLC
    00.00%
  • Carmignac Gestion
    00.00%
  • Allianz Asset Management AG
    00.00%
  • Cinctive Capital Management LP
    00.00%
  • ARP AMERICAS LLC
    00.00%
  • CIBC Global Asset Management Inc
    00.00%

Top Fund Holders

  • iShares Russell 2000 ETF
    2.77M1.79%
  • BlackRock Event Driven Equity Instl
    1.75M1.13%
  • iShares Russell 2000 Growth ETF
    887.88K0.57%
  • NexPoint Merger Arbitrage Z
    824.40K0.53%
  • The Merger Fund A
    817.75K0.53%
  • Vanguard Russell 2000 ETF
    551.07K0.36%
  • Amundi Tiedemann Arbitrage Strat I USD
    529.31K0.34%
  • BSF Global Event Driven Z2 USD
    442.96K0.29%
  • PICTON Arbitrage Plus Alternative Fund F
    346.30K0.22%
  • Vanguard Health Care ETF
    330.29K0.21%
  • Schwab Small Cap Index
    291.62K0.19%